In a separate study, a quantitative structure-activity relationship (QSAR) model was constructed from a dataset of 212 compounds. A consensus model was employed to identify compounds with the highest predicted activity in a database of drug-like ionic liquids generated from synthetic building blocks and reactions. Then, imidazolium and pyridinium compounds were tested against resistant strains of S. aureus, including 8, 9, and 10, obtaining inhibition zones with diameters of 19.7 to 25.3 mm. Nevertheless, determining MIC values can be inconvenient due to multiple protein interactions in bacteria and long chains could be appropriate for InhA enzyme, present in M. tuberculosis. It is noteworthy that these ionic compounds are structurally similar to imidazole and pyridine inhibitors of FabI and exhibit activity comparable to the broad-spectrum antibiotic ceftriaxone . Kuralt and Frlan carried out a cheminformatic analysis on 416 compounds tested with Fab enzymes, where 7% of the active FabI inhibitors were classified as pan-assay interference compounds . Visualization of the chemical space showed the large diversity of FabI inhibitors, not exclusively targeting S. aureus. A matched molecular pair analysis revealed that major structural changes in the chemical structures of the 416 compounds involved hydrophobic groups and uncover 3% of compounds being classified as activity cliffs (ACs) -pairs of highly similar structures with substantial differences in biological activity -, indicating a high rate of transformed compounds with similar activity levels. Additional chemoinformatic analysis revealed that features such as Michael acceptors, alkene groups, and tertiary amides increase the probability of activity against FabI .